DOI QR코드

DOI QR Code

Interferon Apha 2b for Treating Patients with JAK2V617F Positive Polycythemia Vera and Essential Thrombocytosis

  • Zhang, Zhi-Rong (Department of Hematology, Affiliated Hospital of Taishan Medical University) ;
  • Duan, Yan-Chao (Department of Hematology, Affiliated Hospital of Taishan Medical University)
  • Published : 2014.02.28

Abstract

Objective: To investigate interferon (IFN) alpha 2 b for treating patients with JAK2V617F positive polycythemia vera (PV) and essential thrombocytosis (ET). Methods: Interferon alpha 2 b was used to treat patients with JAK2V617F positive PV and ET. In control group, hydroxyurea was used. Endpoint of study was to compare rates of hematological and molecular remission. Results: Patients in the interferon alpha 2 b group achieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, with a lower incidence of thrombosis. Conclusion: Compared with hydroxyurea, interferon alpha 2 b could reduce JAK2V617F load for patients with PV and ET, and achieve higher molecular remission, improve treatment efficacy and reduce complications.

References

  1. Eickelberg O, Pansky A, Koehler E, et al (2001). Molecular mechanisms of TGF- (beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J, 15, 797-806. https://doi.org/10.1096/fj.00-0233com
  2. Rizza P, Moretti F, Belardelli F et al (2010). Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity. 43, 204-9 https://doi.org/10.3109/08916930903510880
  3. Wang Q, Miyakawa Y, Fox N, et al (2000). Interferonalpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood, 96, 2093-9.
  4. Zhao YH, Wang T, Yu GF, et al (2013). Anti-proliferation effects of interferon on gastric cancer cells. Asian Pac J Cancer Prev, 14, 5513-8. https://doi.org/10.7314/APJCP.2013.14.9.5513
  5. Dai CH, Price JO, Brunner T, et al (1998). Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood, 91, 1235-42.
  6. Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5. https://doi.org/10.7314/APJCP.2013.14.3.2101
  7. Guo Y, Wang G, Gao WW, et al (2012). Induction of apoptosis in glioma cells and upregulation of Fas expression using the human interferon gene. Asian Pac J Cancer Prev, 13, 2837-40. https://doi.org/10.7314/APJCP.2012.13.6.2837
  8. Hasselbalch HC (2011). A new era for IFN-$\alpha$ in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol, 4, 637-55. https://doi.org/10.1586/ehm.11.63
  9. Kiladjian JJ, Cassinat B, Chevret S, et al (2008). Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 112, 3065-72. https://doi.org/10.1182/blood-2008-03-143537
  10. Laljee RP, Muddaiah S, Salagundi B, et al (2013). Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. Asian Pac J Cancer Prev, 14, 1147-50. https://doi.org/10.7314/APJCP.2013.14.2.1147
  11. Larsen TS, Pallisgaard N, Moller MB, et al (2007). The JAK2 V617F alleleburden in essential thrombocythemia, polycythemia vera and primary myelofi-brosis - impact on disease phenotype. Eur J Haematol, 79, 508-15. https://doi.org/10.1111/j.1600-0609.2007.00960.x
  12. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al (2013). Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon $\alpha$-2a. Blood, 122, 893-901. https://doi.org/10.1182/blood-2012-07-442012
  13. Bai J, Xue YP, Zhang L, et al (2011). Interferon-alpha-2b Induces Molecular Responses of Patients with Polycythemia Vera and Its Post-polycythemic Myelofibrosis. J Exp Haematol, 19, 444-9.
  14. Barbui T, Finazzi MC, Finazzi G, et al (2012). Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev, 26, 205-11. https://doi.org/10.1016/j.blre.2012.06.002
  15. Barosi G, Birgegard G, Finazzi G, et al (2009). Response criteria for essential thrombocythemia and poly-cythemia vera: result of a European Leukemia Net consensus conference. Blood, 113, 4829-33. https://doi.org/10.1182/blood-2008-09-176818
  16. Chawla-Sarkar M, Lindner DJ, Liu YF, et al (2003). Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis, 8, 237-49. https://doi.org/10.1023/A:1023668705040

Cited by

  1. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7327
  2. Clinico-Hematological Profile and Risk Stratification in Patients with Essential Thrombocythemia: Experience from Pakistan vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7659
  3. Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1053
  4. Clinico-Epidemiological Profile of Patients with Polycythaemia Rubra Vera - a Five Year Experience from a Tertiary Care Center vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1531